These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17516158

  • 1. Effect of T0901317 on hepatic proinflammatory gene expression in apoE-/- mice fed a high-fat/high-cholesterol diet.
    Dai X, Ou X, Hao X, Cao D, Tang Y, Hu Y, Li X, Tang C.
    Inflammation; 2007 Aug; 30(3-4):105-17. PubMed ID: 17516158
    [Abstract] [Full Text] [Related]

  • 2. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
    Ou X, Dai X, Long Z, Tang Y, Cao D, Hao X, Hu Y, Li X, Tang C.
    Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W, Zhang T, Cheng J, Zhou X, Qu X, Hu H.
    Pharmacology; 2010 May; 86(5-6):306-12. PubMed ID: 21071998
    [Abstract] [Full Text] [Related]

  • 5. Synthetic liver X receptor agonist T0901317 inhibits semicarbazide-sensitive amine oxidase gene expression and activity in apolipoprotein E knockout mice.
    Dai X, Ou X, Hao X, Cao D, Tang Y, Hu Y, Li X, Tang C.
    Acta Biochim Biophys Sin (Shanghai); 2008 Mar; 40(3):261-8. PubMed ID: 18330481
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y, Duan Y, Yang X, Sun L, Liu M, Wang Q, Ma X, Zhang W, Li X, Hu W, Miao RQ, Xiang R, Hajjar DP, Han J.
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N.
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [Abstract] [Full Text] [Related]

  • 9. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T.
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [Abstract] [Full Text] [Related]

  • 10. Association between liver X receptor-α and neuron-derived orphan nuclear receptor-1 in Kupffer cells of C57BL/6 mice during inflammation.
    He K, Dai ZY, Li PZ, Zhu XW, Gong JP.
    Mol Med Rep; 2015 Oct; 12(4):6098-104. PubMed ID: 26239564
    [Abstract] [Full Text] [Related]

  • 11. Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells.
    Norata GD, Ongari M, Uboldi P, Pellegatta F, Catapano AL.
    Int J Mol Med; 2005 Oct; 16(4):717-22. PubMed ID: 16142410
    [Abstract] [Full Text] [Related]

  • 12. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS, Murphy AJ, Abramowicz S, Ntonga V, Welch CL, Tall AR, Westerterp M.
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [Abstract] [Full Text] [Related]

  • 13. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro.
    Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N.
    Biochem Biophys Res Commun; 2008 Jun 20; 371(1):114-7. PubMed ID: 18413148
    [Abstract] [Full Text] [Related]

  • 14. Liver X receptor α activation with the synthetic ligand T0901317 reduces lung injury and inflammation after hemorrhage and resuscitation via inhibition of the nuclear factor κB pathway.
    Solan PD, Piraino G, Hake PW, Denenberg A, O'Connor M, Lentsch A, Zingarelli B.
    Shock; 2011 Apr 20; 35(4):367-74. PubMed ID: 20926989
    [Abstract] [Full Text] [Related]

  • 15. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis.
    Naiki Y, Sorrentino R, Wong MH, Michelsen KS, Shimada K, Chen S, Yilmaz A, Slepenkin A, Schröder NW, Crother TR, Bulut Y, Doherty TM, Bradley M, Shaposhnik Z, Peterson EM, Tontonoz P, Shah PK, Arditi M.
    J Immunol; 2008 Nov 15; 181(10):7176-85. PubMed ID: 18981139
    [Abstract] [Full Text] [Related]

  • 16. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice.
    Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K, Friedman TC.
    Endocrinology; 2006 Nov 15; 147(11):5061-8. PubMed ID: 16873540
    [Abstract] [Full Text] [Related]

  • 17. Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity.
    Xu J, Wagoner G, Douglas JC, Drew PD.
    J Leukoc Biol; 2009 Aug 15; 86(2):401-9. PubMed ID: 19406833
    [Abstract] [Full Text] [Related]

  • 18. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
    van der Stoep M, Li Z, Calpe-Berdiel L, van der Sluis RJ, Saleh P, McKinnon HJ, Smit MJ, Korporaal SJ, Van Berkel TJ, Van Eck M, Hoekstra M.
    Biochem Pharmacol; 2013 Dec 01; 86(11):1594-602. PubMed ID: 24095721
    [Abstract] [Full Text] [Related]

  • 19. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.
    Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM.
    J Neurochem; 2004 Feb 01; 88(3):623-34. PubMed ID: 14720212
    [Abstract] [Full Text] [Related]

  • 20. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D, Hiipakka RA, Dai Q, Guo J, Reardon CA, Getz GS, Liao S.
    J Pharmacol Exp Ther; 2008 Nov 01; 327(2):332-42. PubMed ID: 18723776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.